Oral Nifedipine versus Intravenous Labetalol for Acute Blood Pressure Control in Severe Hypertension of Pregnancy: A Study at Faridpur Medical College Hospital
نویسندگان
چکیده
The first line antihypertensive treatment for severe hypertension of pregnancy includes labetalol, hydralazine, or nifedipine. Rapid but safe blood pressure control allows the definitive treatment, delivery baby to be carried out with minimal delay and good maternal fetal outcomes. This non-randomized clinical trial was performed in Faridpur Medical College Hospital compare effectiveness tolerability oral nifedipine intravenous labetalol acute pregnancy. Total 50 admitted pregnant women a viable fetus (>_ 24 weeks gestation) having were allocated into two groups, Group A: 25 patients receiving (10 mg), B: injectable (with incremental doses: 20, 40, 80mg). Up 5 doses tried each drug at 15 minutes interval until target (<_150/100 mmHg) achieved. Baseline characteristics like mean age, weight, heart rate, systolic diastolic pressures similar both groups. average time required achieve 30.33 ± 10.44 25.63 10.12 (p=0.9129). Feto-maternal outcomes adverse related effects among Both found equally effective well tolerated. Nifedipine may preferable as it is simple, flat dose schedule an regimen.
 Med. Coll. J. 2021;16(1):25-29
منابع مشابه
Comparative Study of Intravenous Labetalol and Oral Nifedipine for Control of Blood Pressure in Severe Preeclampsia
Objective: To compare intravenous Labetalol with oral Nifedipine in their rapidity to control hypertensive emergencies of pregnancy. Design: A hospital based prospective randomized interventional comparative study. Methods: Pregnant woman with severe gestational hypertension ≥ 160/110 mm of Hg were randomized to receive intravenous Labetalol injection (in an escalating dose regimen of 20, 40, 8...
متن کاملA comparative evaluation of intravenous labetalol versus oral nifedipine for control of severe pregnancy-induced hypertension with low-dose regimen
Background: Hypertensive disorders complicate 5%–10% of all pregnancies and contribute greatly to maternal morbidity and mortality rates. Dangerous hypertension can cause cerebrovascular hemorrhage, hypertensive encephalopathy, and can trigger eclamptic convulsions. Blood pressure (BP) ≥160/110 mmHg in pregnancy requires prompt treatment. Both nifedipine and intravenous (IV) labetalol are effec...
متن کاملLabetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy: A Randomized Controlled Trial.
Data from randomized controlled trials to guide antihypertensive agent choice for chronic hypertension in pregnancy are limited; this study aimed to compare labetalol and nifedipine, additionally assessing the impact of ethnicity on treatment efficacy. Pregnant women with chronic hypertension (12+0-27+6 weeks' gestation) were enrolled at 4 UK centers (August 2014 to October 2015). Open-label fi...
متن کاملLabetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy
Data to inform prescribing of antihypertensive treatments for chronic hypertension in pregnancy are sparse and subsequently no consensus on the optimal agent(s) exists. The prevalence of chronic hypertension in pregnancy is estimated at 3%, but this figure is set to increase with rising maternal age and the global obesity epidemic. Given that chronic hypertension is associated with significantl...
متن کاملAntihypertensive Drug Therapy for Hypertensive Disorders in Pregnancy
Hypertension in pregnancy is associated with increased maternal and fetal mortality and morbidity. About 8 % of all pregnancies are complicated with hypertensive disorders. There is concordance that severe hypertension should be treated without delay to reduce maternal risks of acute cerebrovascular complications. Intravenous labetalol and oral nifedipine are as effective as intravenous hydrala...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Faridpur Medical College Journal
سال: 2021
ISSN: ['2079-3553', '2312-9093']
DOI: https://doi.org/10.3329/fmcj.v16i1.55733